



Theratechnologies Announces US\$40 Million Bought-Deal Public Offering of Units (Canadian Version)

January 11, 2021

Montreal, QC – January 11, 2021 – Theratechnologies Inc. (“**Theratechnologies**” or the “**Company**”) (TSX: TH) (NASDAQ: THTX) , a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that it has entered into an agreement with Mackie Research Capital Corporation as the lead underwriter and sole bookrunner, on behalf of a syndicate of underwriters, including Canaccord Genuity Corp. and National Bank Financial Inc. (collectively, the “**Underwriters**”), pursuant to which the Underwriters have agreed to purchase, on a bought-deal basis, 14,546,000 units of the Company (the “**Units**”) for aggregate gross proceeds to the Company of US\$40,001,500 (equivalent to approximately C\$51,081,915) (the “**Offering**”) at a price of US\$2.75 per Unit (equivalent to approximately C\$3.51 per Unit).

Each Unit shall be comprised of one common share of the Company (each a “**Common Share**”) and one-half of one Common Share purchase warrant of the Company (each whole warrant, a “**Warrant**”). Each Warrant shall entitle the holder thereof to purchase one Common Share at an exercise price of US\$3.18 (equivalent to approximately C\$4.06) at any time up to 36 months from the closing of the Offering.